NASHUA, N.H., June 17, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced today the closing of its previously announced underwritten registered public offering of 1,881,818 shares of its common stock at a price to the public of $5.50 per share, which includes the exercise of the underwriter’s over-allotment option to purchase 245,454 shares, for gross proceeds of approximately $10.3 million.

After deducting the underwriter’s discount and other estimated offering expenses payable by iCAD, the net proceeds of the offering are approximately $9.5 million.

Craig-Hallum Capital Group acted as sole managing underwriter for the offering. Laidlaw & Company (UK) Ltd. acted as financial advisor for the offering.

About iCAD, Inc.:

Headquartered in Nashua, N.H., iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.